Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 62

Results For "generic"

799 News Found

IPP to organize e-conference on 'Indian Pharma Industry: Developing a conducive ecosystem' on Feb 18
News | February 17, 2022

IPP to organize e-conference on 'Indian Pharma Industry: Developing a conducive ecosystem' on Feb 18

The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies
interviews | February 15, 2022

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post

Zydus gets 180 days of shared exclusivity for Roflumilast tablets
Drug Approval | February 14, 2022

Zydus gets 180 days of shared exclusivity for Roflumilast tablets

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct
News | February 14, 2022

Divi’s Labs Q3 driven by custom synthesis; margins sustainable: ICICI Direct

Key takeaways of recent quarter & conference call highlights

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed
interviews | February 09, 2022

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed

MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India

Lupin receives approval from USFDA for Arformoterol Tartrate inhalation
Drug Approval | February 08, 2022

Lupin receives approval from USFDA for Arformoterol Tartrate inhalation

Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
News | February 07, 2022

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

Key takeaways of recent quarter & conference call highlights

Sun Pharma demonstrates strong performance on all fronts: ICICI Direct
News | February 04, 2022

Sun Pharma demonstrates strong performance on all fronts: ICICI Direct

Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses

Dr. Reddy's set to acquire Nimbus Health
News | February 03, 2022

Dr. Reddy's set to acquire Nimbus Health

The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients

Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
News | January 31, 2022

Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct

ICICI Direct analysis of Dr Reddy’s Q3FY22 results

Latest Stories

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

Bayer’s asundexian demonstrated 26% reduction in stroke after a non-cardioembolic ischemic stroke

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging